盛源控股(00851.HK)漏報購買30.4萬股平保(02318.HK)H股
盛源控股(00851.HK)公布,2022年3月16日及3月17日,集團已於市場上購買總計30.4萬股中國平安保險(02318.HK)H股,每股介乎47.1元至54.2元,總購買價為1,552萬元,每股平均價約51.053元。
於2021年9月8日、15日及16日,附屬建和管理已認購正商票據及Atta票據,本金額為2,958萬美元,包括盛源自營投資及Flourishing Fund認購事項。
公司未能及時報告及公布認購事項及平安股份收購事項之詳情及就認購事項取得股東批准,構成違反上市規則第14A章,澄清違反上市規則是由於無心之失所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.